Welcome to our dedicated page for Revelation Biosciences news (Ticker: REVB), a resource for investors and traders seeking the latest updates and insights on Revelation Biosciences stock.
Revelation Biosciences, Inc. (stock symbol: REVB) is a clinical-stage life sciences company dedicated to advancing immunologic therapeutics and diagnostics designed to improve global health. At the core of its innovative endeavors is Gemini, a proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), an established TLR4 agonist. This formulation is designed to stimulate the body's innate immune response to prevent and treat various diseases.
The company is actively developing a pipeline of high-value product candidates based on this unique Gemini formulation. These programs include:
- Gemini-SSI: Focused on preventing surgical site infections (SSI).
- Gemini-AKI: Aimed at preventing acute kidney injury (AKI).
- Gemini-CKD: Targeted at treating chronic kidney disease (CKD).
Revelation Biosciences, Inc. is committed to leveraging the science of trained immunity through the Gemini-based products to address significant unmet medical needs and improve patient outcomes. The company continues to make strides in their clinical trials and research, aiming for groundbreaking advancements in healthcare.
With a strong focus on innovation and a dedication to enhancing patient health, Revelation Biosciences, Inc. stands as a significant player in the biotech industry, promising solutions to some of the most challenging health conditions.
Revelation Biosciences Inc. (NASDAQ: REVB) has announced a definitive agreement for the immediate exercise of certain outstanding warrants. The exercise will result in $3.8 million in gross proceeds for the company. Key details include:
- Exercise of warrants to purchase up to 2,548,060 shares of common stock
- Reduced exercise price of $1.50 per share
- Issuance of new warrants in a private placement
- New warrants for up to 5,096,120 shares at $1.00 per share
- Five-year term for new warrants
- Roth Capital Partners acting as financial advisor
The company plans to file a resale registration statement within 20 days of closing to register the resale of shares underlying the new warrants.
Revelation Biosciences (NASDAQ: REVB), a clinical-stage biopharmaceutical company, reported its financial results for Q2 and H1 2024. Key highlights include:
- Completed dosing of first-in-human phase 1 clinical study of Gemini
- Announced positive phase 1 clinical data meeting primary safety endpoint
- Cash and cash equivalents of $12.1 million as of June 30, 2024
- Net loss of $8.4 million for Q2 2024, compared to $1.4 million in Q2 2023
- Net loss of $11.1 million for H1 2024, compared to net income of $4.7 million in H1 2023
The company believes its current cash position is sufficient to fund operations through 2024.
Revelation Biosciences announced that its Phase 1 clinical study of Gemini met its primary safety endpoint and showed statistically significant biomarker activity. The study, conducted with 40 healthy volunteers aged 18-55 in Australia, found that Gemini was safe and well-tolerated at pharmacologically active doses. Significant dose-dependent changes in key biomarkers, such as interleukin-1RA, neutrophil gelatinase lipocalin, C-reactive protein, and IL-6, were observed, indicating the drug's immunostimulatory effects. The Phase 1 results support further development across multiple indications, including acute kidney injury prevention and postoperative infection prevention. The maximum tolerated dose identified will guide the upcoming Phase 1b study in chronic kidney disease patients planned for late 2024.
Revelation Biosciences (NASDAQ: REVB) has completed enrollment and dosing of its first-in-human Phase 1 clinical study (RVL-HV02) for Gemini, conducted in Australia.
The study evaluated escalating doses of intravenously administered Gemini in 40 healthy individuals aged 18-55. The forthcoming top-line data will assess safety and tolerability, along with biomarkers to demonstrate immune response stimulation.
Positive data could support Gemini's future development for multiple indications, including reducing acute kidney injury and post-surgical infections.
Preclinical studies have shown promising results in reducing AKI severity and bacterial infections.
Revelation's CEO, James Rolke, highlighted the milestone's significance for addressing critical unmet needs.
Revelation Biosciences, Inc. (NASDAQ: REVB) announced its financial results for the three months ended March 31, 2024. The company reported $14.6 million in cash and cash equivalents, up from $12.0 million in December 2023. They stated that the current cash is enough to fund operations through 2024. However, they reported a net loss of $2.7 million for the quarter, with significant expenses related to GEM-AKI and GEM-SSI clinical studies impacting their financials.
FAQ
What is the current stock price of Revelation Biosciences (REVB)?
What is the market cap of Revelation Biosciences (REVB)?
What is Revelation Biosciences, Inc.?
What is the core technology of Revelation Biosciences, Inc.?
What are the primary programs based on the Gemini formulation?
What is the stock symbol for Revelation Biosciences, Inc.?
What diseases are targeted by Revelation Biosciences, Inc. products?
How does the Gemini formulation work?
Is Revelation Biosciences, Inc. conducting clinical trials?
What is the goal of Revelation Biosciences, Inc.?
Where can I find the latest news about Revelation Biosciences, Inc.?
What makes Revelation Biosciences, Inc. unique in the biotech industry?
